Navigation Links
Delpor Announces Issuance of US Patent Covering its Novel Implantable Device for the Long-Term Delivery of Antipsychotics and other Drugs
Date:3/7/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office issued on February 7, 2017 U.S. Patent No. 9,561,352 covering Delpor’s implantable device for the long-term delivery of therapeutic agents. The device uses Delpor’s proprietary PROZOR™ technology for the sustained release of drugs for several months after subcutaneous implantation. Delpor has several product candidates in development, including a 6-month formulation of risperidone and a 3-month formulation of olanzapine, that are covered by the newly issued patent.

Numerous therapeutic agents including risperidone, olanzapine, asenapine, and other CNS molecules can benefit from long-term sustained delivery. The benefits of such delivery include improved medication adherence, as well as a “smooth” pharmacokinetic profile resulting in enhanced safety and tolerability. Most CNS drugs, as well as other important classes, exhibit poor water solubility at neutral pH, creating challenges to the development of implantable sustained delivery systems which rely on passive diffusion as the primary drug release mechanism. Delpor’s proprietary PROZOR technology enables the release of antipsychotics and other agents for several months through passive diffusion, based on a unique formulation. Furthermore, Delpor’s drug delivery implant device, offers full reversibility if treatment discontinuation is needed due to adverse events.

“The issuance of this patent recognizes the novelty of the underlying technology and marks the beginning of a new family of patents for Delpor, making it a key component of our intellectual property portfolio,” said Tassos Nicolaou, President and CEO of Delpor. “The PROZOR technology overcomes the solubility challenges faced by most CNS drugs, and creates the potential for several sustained release long acting therapeutic products, lasting as long as one year. Our lead risperidone program is currently utilizing this unique approach to create a 6-month formulation of the drug which should result in superior clinical outcomes through improved medication adherence.”

Tassos Nicolaou continued: “If treatment discontinuation is needed due to adverse events, the implant can be easily removed by a healthcare professional, and drug plasma levels drop to zero within a day. Our goal is to further expand the use of this innovative platform for the delivery of other agents including the antipsychotics olanzapine and asenapine”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at http://www.delpor.com.

About PROZOR™
Delpor’s PROZOR technology enables the sustained release of certain insoluble drugs (including most antipsychotics) from a non-mechanical (passive) implantable drug delivery device based on a unique formulation. A typical formulation is a mixture of the drug and a group of excipients designed to regulate the pH over time. The formulation is in the form of an aqueous suspension held within a small cylindrical reservoir fitted at each end with conventional membranes.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/DelporUSPatentIssuance/032017/prweb14124829.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Isabel Healthcare Announces Integration of American Academy of Pediatrics (AAP) Pediatric Care Online™ (PCO) Resources with Isabel Professional
2. Pearson Announces Career Exploration Mentorship Program for Students, Young Professionals with Disabilities
3. CUBA Beverage Company Announces the Launch of New 100% Natural Alkaline Water Product
4. Alliance Healthcare Foundation Announces 26 Recipients of 2017 Mission Support Grant Program
5. OrthAlign, Inc. Announces Full Commercial Launch of UniAlign™, the World’s First Handheld Navigation Device for Use in Unicompartmental Knee Arthroplasty
6. Pearson Announces SXSWedu Conference 2017 Lineup
7. MyTrimLine Announces, Good Day PA to Use Nadia as the Show’s Nutritional Consultant
8. Fiberstar Announces Winners of the Citri-Fi® 125 Citrus Fiber Student Innovation Contest Supporting the Food and Beverage Industry
9. GAO RFID Announces a New Long Range Personnel Tracking System
10. Aloria Health Announces Opening Of Residential Services
11. ACMA Announces New Release of Compass Directional Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... For the second year, ... student to educate the public on the impact of concussions. Brooke Mills, student ... National Concussion Awareness Day. , Brooke is working diligently is to raise awareness ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... partnerships through affiliations and de novo development, today announced Cumberland Skin Surgery ... Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Southeastern Telehealth ... grant totaling $975,000, renewing its funding from the Health Resources and Services Administration ... funding marks, the fourth time the HRSA administration has renewed its financial support ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment of clubfoot, ... all 29 Indian states—bringing the country one step closer to eliminating clubfoot as a ... organization is on track to enroll 10,000 children in the clubfoot treatment program in ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Melbourne’s reign ... by the prestigious Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys ... Since the index began in 2006, Melbourne has consistently come in the top three ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Mich. , Aug. 15, 2017 Diplomat ... naloxone to Michigan residents. ... Flint retail pharmacy, G-3320 Beecher ... approved by the Food and Drug Administration, is intended ... extreme drowsiness, slowed breathing, and loss of consciousness. The ...
(Date:8/15/2017)... WILMINGTON, N.C. , Aug. 15, 2017 ... Wilmington, NC , today announced that the company ... at the University of North Carolina at Chapel Hill ... AccuKit-HIV is designed to characterize and quantify HIV reservoir ... and after pharmacological intervention. The HIV Cure Center is ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
Breaking Medicine Technology: